Pailin Biotechnology: Subsidiary receives Notice of Acceptance of Supplemental Application for Intravenous Human Immunoglobulin Drug.

Paclin Biotechnology Announcement: Recently, the wholly-owned subsidiary Guangdong Shuanglin Biopharmaceutical Co., Ltd. received the "Acceptance Notice" of the supplementary application for intravenous human immunoglobulin drugs approved and issued by the National Medical Products Administration. This application involves three specifications of intravenous human immunoglobulin drugs: 2.5g/bottle, 5g/bottle, and 10g/bottle. The main indications of the drugs include primary immunoglobulin deficiency, secondary immunoglobulin deficiency diseases, and autoimmune diseases. This acceptance will help improve the safety and convenience of clinical medication, aligning the domestic production process with international standards.